Post-CDK4/6 Inhibitor Therapeutic Approaches in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Current Evidence and Emerging Strategies—A Narrative Review

<b>Background</b>: Therapeutic resistance following cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) represents a key unmet need in hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (mBC). Treatment paradigms...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Humaid O. Al-Shamsi, Nadia Abdelwahed, Siddig Ibrahim Abdelwahab, Mawada Hussein, Amin Abyad, Saeed Rafii, Hassan Jaafar, Sonia Otsmane, Dima Abdul Jabbar, Hala Abdellatif, Faryal Iqbal, Mudhasir Ahmad, Hampig Kourie, Kefah Mokbel
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	MDPI AG 2026-06-01
סדרה:	Diagnostics
נושאים:	CDK4/6 inhibitors ESR1 mutations ctDNA elacestrant inavolisib capivasertib
גישה מקוונת:	https://www.mdpi.com/2075-4418/16/12/1790
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!